tradingkey.logo

Hims & Hers Health Inc

HIMS
View Detailed Chart

54.694USD

-0.806-1.45%
Market hours ETQuotes delayed by 15 min
12.35BMarket Cap
63.78P/E TTM

Hims & Hers Health Inc

54.694

-0.806-1.45%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.45%

5 Days

+12.98%

1 Month

+16.05%

6 Months

+65.04%

Year to Date

+126.20%

1 Year

+230.08%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
17 / 72
Overall Ranking
133 / 4724
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 14 analysts
Hold
Current Rating
50.372
Target Price
-9.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical records system, digital prescriptions and cloud-enabled pharmacy fulfillment. Its digital platform enables access to treatments for a range of conditions, including sexual health, men’s and women’s dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services. It offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It offers pharmacy operation capabilities through its MedisourceRx, a 503B outsourcing facility in California.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 180.22% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD 126.04M.%!(EXTRA int=2)
Fairly Valued
The company’s latest PE is 62.95, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 201.00M shares, decreasing 14.69% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 18.63M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.72.

News

Hims & Hers Health Inc (HIMS): The Opportunity is still Strong and Potent

TradingKey - Despite the whole controversy with NVO, we believe HIMS is able to achieve 6 million subscribers and $6 billion of revenue by 2030, due to the large opportunity of growth for the telehealth industry, early investments in logistics capabilities and ability to upsell their patients.

TradingKeyMon, Sep 1
TradingKey - Despite the whole controversy with NVO, we believe HIMS is able to achieve 6 million subscribers and $6 billion of revenue by 2030, due to the large opportunity of growth for the telehealth industry, early investments in logistics capabilities and ability to upsell their patients.

US FTC investigating Hims & Hers over advertising and cancellation practices, Bloomberg News reports

Aug 14 (Reuters) - The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers HIMS.N regarding its advertising and cancellation practices, according to a Bloomberg News report citing people familiar with the matter.

ReutersFri, Aug 15
Aug 14 (Reuters) - The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers HIMS.N regarding its advertising and cancellation practices, according to a Bloomberg News report citing people familiar with the matter.

Hims & Hers: A Game-Changer in Telehealth or Just Another Fad?

Explore the exciting world of Hims & Hers (NYSE: HIMS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

OtherFri, Aug 8
Explore the exciting world of Hims & Hers (NYSE: HIMS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

“King of Knockoff Weight-Loss Drugs” Still Struggling — Hims & Hers Misses Revenue, Stock Drops 12% After Hours

TradingKey - Despite a 73% year-on-year revenue increase in Q2 2025 that highlights the growth potential of the digital health sector, Hims & Hers (HIMS), a high-profile player in the AI-driven telehealth space, continues to face mounting legal and operational challenges. The negative impact on its

TradingKeyTue, Aug 5
TradingKey - Despite a 73% year-on-year revenue increase in Q2 2025 that highlights the growth potential of the digital health sector, Hims & Hers (HIMS), a high-profile player in the AI-driven telehealth space, continues to face mounting legal and operational challenges. The negative impact on its

Novo Nordisk Terminates Weight-Loss Drug Partnership with Hims&Hers – NVO Drops 7%, HIMS Plummets 25%

TradingKey - Just two months into their weight-loss drug partnership, Novo Nordisk (NVO) announced on Monday, June 23, that it is terminating its collaboration with telehealth company Hims&Hers (HIMS). The move sent shockwaves through the market, with shares of the so-called "AI + healthcare" growth

TradingKeyMon, Jun 23
TradingKey - Just two months into their weight-loss drug partnership, Novo Nordisk (NVO) announced on Monday, June 23, that it is terminating its collaboration with telehealth company Hims&Hers (HIMS). The move sent shockwaves through the market, with shares of the so-called "AI + healthcare" growth

HIMS: When Overvaluation Isn’t What It Seems

TradingKey - The stock market is sending mixed messages about Hims & Hers Health (HIMS). On the plus side, the shares are trading higher by approximately 16% for the day, continuing a red-hot YTD run; on the other, the stock looks overvalued on paper with GAAP P/E and EV/EBITDA multiples several tim

TradingKeyFri, May 23
TradingKey - The stock market is sending mixed messages about Hims & Hers Health (HIMS). On the plus side, the shares are trading higher by approximately 16% for the day, continuing a red-hot YTD run; on the other, the stock looks overvalued on paper with GAAP P/E and EV/EBITDA multiples several tim

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical records system, digital prescriptions and cloud-enabled pharmacy fulfillment. Its digital platform enables access to treatments for a range of conditions, including sexual health, men’s and women’s dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services. It offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It offers pharmacy operation capabilities through its MedisourceRx, a 503B outsourcing facility in California.
Ticker SymbolHIMS
CompanyHims & Hers Health Inc
CEOMr. Andrew Dudum
Websitehttps://www.forhims.com/
KeyAI